Search Results - "Leonardi, C.L."

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3) by Papp, K.A., Leonardi, C.L., Blauvelt, A., Reich, K., Korman, N.J., Ohtsuki, M., Paul, C., Ball, S., Cameron, G.S., Erickson, J., Zhang, L., Mallbris, L., Griffiths, C.E.M.

“…Summary Background Ixekizumab, a high‐affinity monoclonal antibody that selectively targets interleukin (IL)‐17A, is approved for the treatment of…”
Get full text

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches by Blauvelt, A., Lacour, J.‐P., Fowler, J.F., Weinberg, J.M., Gospodinov, D., Schuck, E., Jauch‐Lembach, J., Balfour, A., Leonardi, C.L.

“…Summary Background Adalimumab is used to treat several inflammatory diseases, including plaque psoriasis. GP2017 is a proposed adalimumab biosimilar…”
Get full text

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method by Mrowietz, U., Warren, R.B., Leonardi, C.L., Saure, D., Petto, H., Hartz, S., Dossenbach, M., Reich, K.

“…Background In practice, the goal of treatment for patients with psoriasis is to achieve almost clear or clear skin and maintain disease control, regardless of…”
Get full text

Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR) by Blauvelt, A., Ferris, L.K., Yamauchi, P.S., Qureshi, A., Leonardi, C.L., Farahi, K., Fakharzadeh, S., Hsu, M.‐C., Li, S., Chevrier, M., Smith, K., Goyal, K., Chen, Y., Muñoz‐Elías, E.J., Callis Duffin, K.

“…Summary Background Phase III studies showed that some patients maintained response for ≥ 6 months following ustekinumab discontinuation. Objectives To assess…”
Get full text

Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER‐2 and UNCOVER‐3 by Leonardi, C.L., Blauvelt, A., Sofen, H.L., Gooderham, M., Augustin, M., Burge, R., Zhu, B., Reich, K.

“…Background Patients with moderate‐to‐severe psoriasis report impaired health‐related quality of life (HRQoL). Objective To assess speed of onset of…”
Get full text

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2 by Fernandez, A.P., Dauden, E., Gerdes, S., Lebwohl, M.G., Menter, M.A., Leonardi, C.L., Gooderham, M., Gebauer, K., Tada, Y., Lacour, J.P., Bianchi, L., Egeberg, A., Pau‐Charles, I., Mendelsohn, A.M., Rozzo, S.J., Mehta, N.N.

“…Background Limited data are available on long‐term efficacy and safety of biologics in patients with psoriasis and metabolic syndrome (MetS), a common…”
Get full text

伊赛珠单抗对银屑病的治疗:三项双盲对照研究的综合药效分析(发现-1、发现-2、发现-3) by Papp, K.A., Leonardi, C.L., Blauvelt, A., Reich, K., Korman, N.J., Ohtsuki, M., Paul, C., Ball, S., Cameron, G.S., Erickson, J., Zhang, L., Mallbris, L., Griffiths, C.E.M.

Get full text

Long‐term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis by Gniadecki, R., Leonardi, C.L., Gordon, K.B., Gu, Y., Geng, Z., Nader, A., Teixeira, H.D.

“…Background The recently updated dosing recommendation for adalimumab for moderate to severe plaque psoriasis states that patients with inadequate response to…”
Get full text

A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab by Edson-Heredia, E., Banerjee, S., Zhu, B., Maeda-Chubachi, T., Cameron, G.S., Shen, W., Heffernan, M.P., Gordon, K.B., Leonardi, C.L.

Get full text

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3) by Papp, K.A., Leonardi, C.L., Blauvelt, A., Reich, K., Korman, N.J., Ohtsuki, M., Paul, C., Ball, S., Cameron, G.S., Erickson, J., Zhang, L., Mallbris, L., Griffiths, C.E.M.

“…Summary Psoriasis is a disease that causes the skin to form thick scales that get red, itchy, and dry. About 2–4% of the Western population has psoriasis. We…”
Get full text

The tumour necrosis factor-α inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques by Gordon, K.B., Bonish, B.K., Patel, T., Leonardi, C.L., Nickoloff, B.J.

“…Summary Background  The pathophysiology of psoriasis is poorly understood, and the mechanism of action of biological agents interfering with tumour necrosis…”
Get full text

伊赛珠单抗对银屑病的治疗:三项双盲对照研究的综合药效分析(发现‐1、发现‐2、发现‐3) by Papp, K.A., Leonardi, C.L., Blauvelt, A., Reich, K., Korman, N.J., Ohtsuki, M., Paul, C., Ball, S., Cameron, G.S., Erickson, J., Zhang, L., Mallbris, L., Griffiths, C.E.M.

“…Summary…”
Get full text

Efalizumab‐induced autoimmune pancytopenia by Tom, W.L., Miller, M.D., Hurley, M.Y., Suneja, T., Kudva, G., Leonardi, C.L., Obadiah, J.M.

“…Summary Efalizumab is a recombinant, humanized monoclonal anti‐CD11a antibody used for the treatment of moderate to severe plaque psoriasis. Immune‐mediated…”
Get full text

Interface dermatitis in acute varicella-zoster virus infection: demonstration of varicella-zoster virus DNA in keratinocytes by in situ polymerase chain reaction by Nahassf, G.T., Penneys, N.S., Leonardi, C.L.

Get full text

Detection of mycobacterium paratuberculosis by polymerase chain reaction in patients with Crohn's disease versus controls: An updated report by Petersen, P.F., Zachary, P.E., Clarkston, W.K., Presti, M.E., Fan, W.X., Leonardi, C.L., Vernava, A.M., Longo, W.E., Kreeger, J.M.

Get full text

Interface dermatitis in acute varicella-zoster virus infection: demonstration of varicella-zoster virus DNA in keratinocytes by in situ polymerase chain reaction by Nahassf, G.T., Penneys, N.S., Leonardi, C.L.

Get full text

Lack of tropomyosin correlates with the absence of stress fibers in transformed rat kidney cells by Leonardi, C L, Warren, R H, Rubin, R W

“…We have utilized epithelial rat kidney cells and their Kirsten viral transformant (442) to examine the role of actin-binding proteins in cellular…”
Get more information

Efalizumab-induced autoimmune pancytopenia by Tom, W.L., Miller, M.D., Hurley, M.Y., Suneja, T., Kudva, G., Leonardi, C.L., Obadiah, J.M.

Get full text

Two-dimensional polyacrylamide gel electrophoresis of membrane proteins by Rubin, R W, Leonardi, C L

Get more information